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INTRODUCTION

47
Bacteriophage are the most abundant biological entity on the planet and impart strong selective 48 pressure on their bacterial hosts. In addition to innate defense systems, bacteria have 49 developed adaptive immunity known as CRISPR-Cas to recognize and destroy foreign nucleic 7 2014), it is evident that interfering with the PAM-binding sites deployed by AcrIIA2 (as also seen 150 in AcrIIA4) is an effective means to abolish Cas9-mediated target DNA binding and cleavage 151 activities. To test whether PAM-recognition blockage confers SpyCas9 inhibition by AcrIIA2, we 152 generated single (D71A) or double mutations (T94A/N95A) of AcrIIA2 residues involved in 
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In addition to interactions with the PAM-binding site, AcrIIA2 makes extensive contacts 160 with the Helical domain I & II and the other parts of the C-terminal domain from SpyCas9 (Table   161 S2). Specifically, residues H15, N19, E26, and T28 in the N-terminal a1-a2 of AcrIIA2 make 
167
bound and AcrIIA2-bound SpyCas9 reveals that AcrIIA2's a1 helix wedges between the target 168 strand and nontarget DNA strand, whereas a2 helix penetrates the interface between +1 169 phosphate lock loop and target DNA strand ( Figure 2D ). These structural observations indicate 170 that AcrIIA2 binding may also disrupt the target DNA unwinding activity of CRISPR-Cas9 in 171 addition to blocking DNA binding. Indeed, mutational substitution of these residues 172 (D38A/D40A) has demonstrated a large reduction in effectiveness of AcrIIA2 as a Cas9 gene 173 drive inhibitor (Basgall et al., 2018). Apart from these structural features, it is also noteworthy 8 that AcrIIA2 does not interfere with the RuvC active site as observed in AcrIIA4-bound structure 175 ( Figure 2F ).
176
We tested and confirmed that AcrIIA2 abrogates SpyCas9-DNA binding by performing 177 gel shift competition assays. Wild-type SpyCas9-sgRNA was used together with 10 mM EDTA 178 to prevent target DNA cleavage. As anticipated, the competition binding experiment with AcrIIA2 179 and target DNA added simultaneously to SpyCas9-sgRNA resulted in an attenuation or 180 elimination of the dsDNA-bound SpyCas9-sgRNA ternary complex in a concentration dependent 181 manner ( Figure 3B ). Furthermore, AcrIIA2 showed a weak competitive binding effect compared 182 to AcrIIA4 ( Figure S10A Notably, residue Y67 of AcrIIA4 participates in the hydrogen bond network within the PAM-197 recognition site of SpyCas9, while Y41 forms hydrophobic and van der Waals interactions. We 198 speculate that lack of these bulky hydrophobic residues may result in the lower effectiveness of 199 AcrIIA2-mediated Cas9 inhibition as seen in vivo.
9
We then compared the Cas9-inhibitory activity of AcrIIA2 and AcrIIA4 by in vitro DNA 201 cleavage assay. Previous in vivo studies showed that AcrIIA4 can completely inactivate Cas9 
241
showed significantly stronger inhibition of SpyCas9 activity in comparison to AcrIIA2a, with 242 AcrIIA2b.3 performing as well as AcrIIA4 ( Figure 4C ). Of note, expression of a protein from the 243 AcrIIA2c family was toxic in P. aeruginosa and thus not pursued further. AcrIIA2b.1 did not 244 express in E. coli and therefore we chose AcrIIA2b.3 (henceforth referred to as AcrIIA2b) for 245 further biochemical analysis.
246
AcrIIA2b protein inactivates SpyCas9 function in a similar fashion to AcrIIA2 through 247 direct interaction with sgRNA-loaded SpyCas9 (Figure S1D-1F ). We next examined the extent 248 to which AcrIIA2b can suppress SpyCas9-mediated DNA cleavage in vitro. In excellent 249 agreement with our in vivo results, AcrIIA2b displays more robust inhibitory capacity against Importantly, the inhibition exhibited by AcrIIA2b at all tested conditions was similar, if not better, 252 than AcrIIA4 ( Figure 4D ). Competitive binding assays showed that AcrIIA2b competes with 253 target DNA for binding to SpyCas9 when added to the enzyme simultaneously ( Figure S10A To determine the underlying structural basis for AcrIIA2b-mediated SpyCas9 inhibition,
264
we determined the cryo-EM structure of the SpyCas9-sgRNA complex bound to AcrII2b at ~3.9 265 Å resolution ( Figures 5A-B and S4B ). In the SpyCas9-sgRNA-AcrIIA2b complex, AcrIIA2b is 266 positioned in the PAM duplex DNA binding cleft, between the NUC and REC lobes. It occupies 267 the same position as that occupied by AcrIIA2 ( Figures 5C and S9B ), although AcrIIA2b buries 268 a larger solvent-accessible surface area (∼2,407Å 2 ) upon ternary complex formation relative to 269 AcrIIA2-Cas9 interface (∼1,803Å 2 ) ( Figure S7A, D) . Despite a large sequence disparity,
270
AcrIIA2b shares the same fold (a1a2b1b2b3a3b4) as AcrIIA2, and its overall structure is similar 271 (Figures S7C, S7F, and S9C ). Divergent loop regions form the binding crevice ( Figure S7B , 272 S7E, and S9C). Additionally, the SpyCas9 conformation observed in the AcrIIA2b-bound 273 structure is nearly identical to that observed in the AcrIIA2-bound structure ( Figure 5C 
12
Although AcrIIA2b utilizes a nearly identical binding mode to that deployed by AcrIIA2 to 277 inhibit SpyCas9 enzymatic activity, a closer inspection of the AcrIIA2b binding crevice near the 278 PAM-interacting site revealed a distinct local environment for interference with PAM recognition.
279
Specifically, the two hydrophobic aromatic amino acid residues (Y39 and F94 in AcrIIA2b) that 280 are engaged in hydrophilic and hydrophobic interactions with SpyCas9's PAM-interacting 281 residues are either not present or not involved in interfering with PAM recognition by AcrIIA2 282 ( Figure 5E ). Interestingly, this interaction pattern of AcrIIA2b bears a striking resemblance to 283 that of AcrIIA4 ( Figure 5F ), although the two anti-CRISPRs are evolutionarily unrelated.
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Additionally, the residues that AcrIIA2b and AcrIIA4 bind are well evolutionarily conserved in 285 Cas9 orthologues from across Listeria to closely related Cas9 orthologues from Enterococcus 286 species ( Figure 5G , S15 and S16). Based on these structural observations, we deduced that the 287 presence of aromatic hydrophobic residues in the PAM-interacting site may contribute to the 288 prominent in vitro and in vivo inhibitory function exerted by both AcrIIA2b and AcrIIA4, and that 289 loss of this extensive hydrophobic interaction pattern in the AcrIIA2-Cas9 interface makes it 290 less stable and therefore less effective for inhibiting SpyCas9 function.
291
To test this idea, we performed temperature-and urea-induced denaturation 292 experiments on the SpyCas9-sgRNA-AcrIIA2b ternary complex and found that AcrIIA2b-
293
SpyCas9 binding is more resistant to denaturation than is AcrIIA2a-SpyCas9 binding. To further 294 assess the importance of individual residues for the inhibitory function of AcrIIA2b, we designed 299 and S17). In vitro, the Y39A/F94A double mutant showed a modest reduction in AcrIIA2b 300 inhibition activity and more importantly, it displayed a more pronounced temperature-dependent 301 anti-CRISPR activity, with the inhibition entirely ablated at body temperature (Figures 6B, S13B 302 13 and S14). We concluded that the pattern of hydrophobic and hydrophilic residues surrounding 303 the PAM-binding site is important to the function of anti-CRISPRs, and that anti-CRISPR 304 stability and efficiency can be altered by large hydrophobic aromatic amino acid residues. 
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We expect that AcrIIA2 can be employed in a similar manner to AcrIIA4 for regulating Cas9 in 336 vivo genome editing. The reduced temperature sensitivity of AcrIIA2b relative to AcrIIA2a 337 supports the use of AcrIIA2b for future applications due to more robust inhibitory activity. Our 
